Innoviva, Inc.
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $119.60M | $-1.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $98.00M | $2.22 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | During market hours | $114.60M | $1.94 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | $107.80M | $1.08 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $100.28M | $0.77 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $89.51M | $0.02 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| IST U.S. net product sales | 2026 | $150.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Innoviva filed with the SEC
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports Third Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports Second Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports Third Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports Second Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Thank you Investor contact: [email protected] Media contact: [email protected]
Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2024 Financial Results; Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Zoliflodacin Phase 3 clinical trial topline data November 2, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Innoviva Appoints Stephen Basso as Chief Financial
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Innoviva Reports Second Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Thank you Investor contact: [email protected] Media contact: [email protected]
Regulation FD disclosure · EX-99.1 to Form 8-K
Innoviva Reports First Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Innoviva Announces Retirement of Board Chairman
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Innoviva Reports Fourth Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Innoviva Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
The information presented below supplements the
Other events · EX-99.1 to Form 8-K
Innoviva Reports Second Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full
Material agreement · Other events · EX-99.1 to Form 8-K
Innoviva Completes Acquisition of Entasis Therapeutics
Acquisition or disposition completed · Other events · EX-99.2 to Form 8-K
Innoviva to Acquire La Jolla Pharmaceutical Company
Material agreement · Other events · EX-99.1 to Form 8-K
This TENDER AND SUPPORT AGREEMENT (this
Material agreement · Other events · EX-99.1 to Form 8-K
This TENDER AND SUPPORT AGREEMENT (this
Material agreement · Other events · EX-99.2 to Form 8-K
Innoviva to Acquire Entasis Therapeutics
Material agreement · Other events · EX-99.3 to Form 8-K
Innoviva Reports First Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Important information On March 25, 2022, the Company filed a Definitive Proxy Statement on Schedule 14A
Regulation FD disclosure · EX-99.1 to Form 8-K
Innoviva Announces Proposed Offering of $200
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125%
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Innoviva Reports Fourth Quarter 2021 Financial
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K